TY - JOUR
T1 - Formate overflow drives toxic folate trapping in MTHFD1 inhibited cancer cells
AU - Green, Alanna C
AU - Marttila, Petra
AU - Kiweler, Nicole
AU - Chalkiadaki, Christina
AU - Wiita, Elisée
AU - Cookson, Victoria
AU - Lesur, Antoine
AU - Eiden, Kim
AU - Bernardin, François
AU - Vallin, Karl S A
AU - Borhade, Sanjay
AU - Long, Maeve
AU - Ghahe, Elahe Kamali
AU - Jiménez-Alonso, Julio J
AU - Jemth, Ann-Sofie
AU - Loseva, Olga
AU - Mortusewicz, Oliver
AU - Meyers, Marianne
AU - Viry, Elodie
AU - Johansson, Annika I.
AU - Hodek, Ondřej
AU - Homan, Evert
AU - Bonagas, Nadilly
AU - Ramos, Louise
AU - Sandberg, Lars
AU - Frödin, Morten
AU - Moussay, Etienne
AU - Slipicevic, Ana
AU - Letellier, Elisabeth
AU - Paggetti, Jérôme
AU - Sørensen, Claus Storgaard
AU - Helleday, Thomas
AU - Henriksson, Martin
AU - Meiser, Johannes
N1 - © 2023. The Author(s).
PY - 2023
Y1 - 2023
N2 - Cancer cells fuel their increased need for nucleotide supply by upregulating one-carbon (1C) metabolism, including the enzymes methylenetetrahydrofolate dehydrogenase-cyclohydrolase 1 and 2 (MTHFD1 and MTHFD2). TH9619 is a potent inhibitor of dehydrogenase and cyclohydrolase activities in both MTHFD1 and MTHFD2, and selectively kills cancer cells. Here, we reveal that, in cells, TH9619 targets nuclear MTHFD2 but does not inhibit mitochondrial MTHFD2. Hence, overflow of formate from mitochondria continues in the presence of TH9619. TH9619 inhibits the activity of MTHFD1 occurring downstream of mitochondrial formate release, leading to the accumulation of 10-formyl-tetrahydrofolate, which we term a 'folate trap'. This results in thymidylate depletion and death of MTHFD2-expressing cancer cells. This previously uncharacterized folate trapping mechanism is exacerbated by physiological hypoxanthine levels that block the de novo purine synthesis pathway, and additionally prevent 10-formyl-tetrahydrofolate consumption for purine synthesis. The folate trapping mechanism described here for TH9619 differs from other MTHFD1/2 inhibitors and antifolates. Thus, our findings uncover an approach to attack cancer and reveal a regulatory mechanism in 1C metabolism.
AB - Cancer cells fuel their increased need for nucleotide supply by upregulating one-carbon (1C) metabolism, including the enzymes methylenetetrahydrofolate dehydrogenase-cyclohydrolase 1 and 2 (MTHFD1 and MTHFD2). TH9619 is a potent inhibitor of dehydrogenase and cyclohydrolase activities in both MTHFD1 and MTHFD2, and selectively kills cancer cells. Here, we reveal that, in cells, TH9619 targets nuclear MTHFD2 but does not inhibit mitochondrial MTHFD2. Hence, overflow of formate from mitochondria continues in the presence of TH9619. TH9619 inhibits the activity of MTHFD1 occurring downstream of mitochondrial formate release, leading to the accumulation of 10-formyl-tetrahydrofolate, which we term a 'folate trap'. This results in thymidylate depletion and death of MTHFD2-expressing cancer cells. This previously uncharacterized folate trapping mechanism is exacerbated by physiological hypoxanthine levels that block the de novo purine synthesis pathway, and additionally prevent 10-formyl-tetrahydrofolate consumption for purine synthesis. The folate trapping mechanism described here for TH9619 differs from other MTHFD1/2 inhibitors and antifolates. Thus, our findings uncover an approach to attack cancer and reveal a regulatory mechanism in 1C metabolism.
U2 - 10.1038/s42255-023-00771-5
DO - 10.1038/s42255-023-00771-5
M3 - Journal article
C2 - 37012496
VL - 5
SP - 642
EP - 659
JO - Nature Metabolism
JF - Nature Metabolism
SN - 2522-5812
IS - 4
ER -